Pfizer (PFE) Q2 2025 earnings report

Pfizer On Tuesday, full -year -old profit guidance on cost deductions and strong business performance this year.

The company also reported the second quarter results exceeding the Wall Street forecasts for the revenue from Covid products and some other drugs.

Pfizer shares increased by more than 2% in premmarket trade on Tuesday.

Pfizer now expects the full -year -old profit to be between $ 2.80 and $ 3 per share between $ 2.90 and $ 3.10. The company kept its 2025 income estimation between 61 billion dollars and $ 64 billion.

Pfizer CFO David Denton said in a statement, “Full year 2025 has increased our armed EPS guidance, we have confiscated our ability to execute and provide strong results for our strategic priorities.” He said.

The full year appearance contains a one -time $ 1.35 billion dollars or 20 cents per share with the company’s 3SBIO, a Chinese drug producer, a Chinese drug producer for developing and selling cancer treatment outside China. Pfizer said this accusation will be recorded in the third quarter.

The results also support Pfizer and other drug producers for the planned tariffs on the drugs imported to the country when president Donald Trump calls for reducing drug prices in the United States.

Pfizer’s appearance, Trump’s tariffs to China, Canada and Mexico, and this year’s potential drug price changes, a letter of a controversial plan of Trump in May, which called on Pfizer to step down until September 29th, to reduce the policy of Trump, to reduce the policy.

The release of Pfizer on Tuesday did not provide special costs for these factors. In April, Pfizer executives said the company’s 2025 guidance contained $ 150 million for the expected costs from Trump’s existing tariffs, but it did not contain industry -specific taxes.

Based on a questionnaire of LSEG’s analysts, the company reported when the Wall Street expects for the second quarter:

• Earning per share: 78 cents set and 58 cents are expected
• Revenues: 14.65 billion dollars and 13.56 billion dollars expected

For the second quarter, Pfizer earned $ 2.91 billion per share or 51 cents net revenue. This is compared with a net income of 41 million dollars or 1 century per share in the same period.

Except for certain items, including reconstruction fees and costs related to intangible assets, the company has earned 78 cents per share for a quarter.

Pfizer reported an increase of 10% for the second quarter compared to the same period of the previous year and reported $ 14.65 billion.

The results have come after Pfizer expanded the efforts of Pfizer, the pharmaceutical giant for the last few years to help to get rid of the rapid decline in Covid business and stock price. With the added deductions announced in April, Pfizer expects about $ 7.7 billion from two separate cost reduction program by the end of 2027.